---
title: "SINO BIOPHARM: \"TQC3721 (PDE3/4 inhibitor)\", \"TQC2731 (TSLP monoclonal antibody)\" and a total of 3 research data will be announced at ERS 2024"
description: "SINO BIOPHARM announced that it will showcase three research data on its two innovative drugs, \"TQC3721 (PDE3/4 inhibitor)\" and \"TQC2731 (TSLP monoclonal antibody)\", at the European Respiratory Societ"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/212518705.md"
published_at: "2024-08-26T08:54:03.000Z"
---

# SINO BIOPHARM: "TQC3721 (PDE3/4 inhibitor)", "TQC2731 (TSLP monoclonal antibody)" and a total of 3 research data will be announced at ERS 2024

> SINO BIOPHARM announced that it will showcase three research data on its two innovative drugs, "TQC3721 (PDE3/4 inhibitor)" and "TQC2731 (TSLP monoclonal antibody)", at the European Respiratory Society Annual Congress (ERS 2024) in 2024. TQC3721, an inhaled PDE3/4 inhibitor, has completed Phase I and Phase IIa clinical trials and will present its key abstract in poster form. TQC2731 is currently undergoing Phase II clinical trials, with its Phase I data also being released at the conference. This achievement marks a significant development for the company in the field of respiratory medicine

According to the news from Zhitong Finance and Economics APP, SINO BIOPHARM (01177) announced that the group's two innovative drugs, "TQC3721 (PDE3/4 inhibitor)" and "TQC2731 (TSLP monoclonal antibody)", will unveil 3 research results at the 2024 European Respiratory Society Annual Congress (ERS2024) from September 7th to 11th.

TQC3721 is an inhaled PDE3/4 inhibitor intended for the maintenance treatment of chronic obstructive pulmonary disease (COPD), with its research progress ranking second globally among drugs targeting the same pathway. Currently, TQC3721 has completed Phase I and Phase IIa clinical trials, and its research data will be presented in the form of posters at ERS 2024, including one as a Late Breaking Abstract.

TQC2731 is a TSLP monoclonal antibody currently undergoing Phase II clinical trials in patients with asthma, chronic sinusitis with nasal polyps, positioning its research progress at the forefront globally. The Phase I study data will be presented in the form of posters at ERS2024.

ERS is the world's largest professional conference in the respiratory field, and the selection of these 3 research results for ERS 2024 demonstrates the breakthrough progress the group has made in the respiratory field. In the future, the group will continue to focus on the respiratory field, continuously exploring new innovative drugs and treatment solutions

### Related Stocks

- [01177.HK - SINO BIOPHARM](https://longbridge.com/en/quote/01177.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 早盘趋势｜中国生物制药回踩低点，反弹窗口会否开启？ | 中国生物制药（1177.HK）近期股价持续低位震荡整理，日线呈现小幅阴阳交替，整体重心下移。近几个交易日，股价回踩至前低区间附近，成交量持续萎缩，场内增量资金观望情绪浓厚。从技术面看，MACD 指标依旧死叉，绿柱显著，短线多空分歧较大。 基 | [Link](https://longbridge.com/en/news/274491341.md) |
| 早盘趋势｜中国生物制药回踩低点，反弹窗口会否开启？ | 中国生物制药（1177.HK）近期股价持续低位震荡整理，日线呈现小幅阴阳交替，整体重心下移。近几个交易日，股价回踩至前低区间附近，成交量持续萎缩，场内增量资金观望情绪浓厚。从技术面看，MACD 指标依旧死叉，绿柱显著，短线多空分歧较大。 基 | [Link](https://longbridge.com/en/news/274496124.md) |
| 早盘趋势｜中国生物制药回踩低点，反弹窗口会否开启？ | 中国生物制药（1177.HK）近期股价持续低位震荡整理，日线呈现小幅阴阳交替，整体重心下移。近几个交易日，股价回踩至前低区间附近，成交量持续萎缩，场内增量资金观望情绪浓厚。从技术面看，MACD 指标依旧死叉，绿柱显著，短线多空分歧较大。 基 | [Link](https://longbridge.com/en/news/274494597.md) |
| 早盘趋势｜中国生物制药回踩低点，反弹窗口会否开启？ | 中国生物制药（1177.HK）近期股价持续低位震荡整理，日线呈现小幅阴阳交替，整体重心下移。近几个交易日，股价回踩至前低区间附近，成交量持续萎缩，场内增量资金观望情绪浓厚。从技术面看，MACD 指标依旧死叉，绿柱显著，短线多空分歧较大。 基 | [Link](https://longbridge.com/en/news/274492204.md) |
| 早盘趋势｜中国生物制药回踩低点，反弹窗口会否开启？ | 中国生物制药（1177.HK）近期股价持续低位震荡整理，日线呈现小幅阴阳交替，整体重心下移。近几个交易日，股价回踩至前低区间附近，成交量持续萎缩，场内增量资金观望情绪浓厚。从技术面看，MACD 指标依旧死叉，绿柱显著，短线多空分歧较大。 基 | [Link](https://longbridge.com/en/news/274488261.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.